CDKN2A mutations are also responsible for 11% of MAPK-reactivating mechanisms of resistance among disease-progressive melanomas described by Shi [74] et al., while a lower copy number of CDKN2A was associated with shorter progression-free survival of patients treated with dabrafenib [65]. This evidence concerns the gene CDKN2A and melanoma.